Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants

被引:0
作者
Chumeng Wang
Akshara Ramasamy
Monica Verduzco-Gutierrez
W. Michael Brode
Esther Melamed
机构
[1] University of Texas at Austin,Department of Neurology, Dell Medical School
[2] University of Texas at San Antonio,Department of Physical Medicine and Rehabilitation
[3] University of Texas at Austin,Department of Internal Medicine, Dell Medical School
来源
Virology Journal | / 20卷
关键词
COVID-19; PASC; Long-COVID; Risk factors; Social determinants;
D O I
暂无
中图分类号
学科分类号
摘要
SARS-CoV-2 infection leading to Coronavirus Disease 2019 (COVID-19) has caused more than 762 million infections worldwide, with 10–30% of patients suffering from post-acute sequelae of SARS-CoV-2 infections (PASC). Initially thought to primarily affect the respiratory system, it is now known that SARS-CoV-2 infection and PASC can cause dysfunction in multiple organs, both during the acute and chronic stages of infection. There are also multiple risk factors that may predispose patients to worse outcomes from acute SARS-CoV-2 infection and contribute to PASC, including genetics, sex differences, age, reactivation of chronic viruses such as Epstein Barr Virus (EBV), gut microbiome dysbiosis, and behavioral and lifestyle factors, including patients’ diet, alcohol use, smoking, exercise, and sleep patterns. In addition, there are important social determinants of health, such as race and ethnicity, barriers to health equity, differential cultural perspectives and biases that influence patients’ access to health services and disease outcomes from acute COVID-19 and PASC. Here, we review risk factors in acute SARS-CoV-2 infection and PASC and highlight social determinants of health and their impact on patients affected with acute and chronic sequelae of COVID-19.
引用
收藏
相关论文
共 258 条
[1]  
Choo SY(2007)The HLA System: Genetics, Immunology, Clinical Testing, and clinical implications Yonsei Med J 48 11-23
[2]  
Phetsouphanh C(2022)Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection Nat Immunol Nature Publishing Group 23 210-6
[3]  
Darley DR(2001)Sex hormones as immunomodulators in health and disease Int Immunopharmacol 1 983-93
[4]  
Wilson DB(2010)The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases Ann N Y Acad Sci 1193 36-42
[5]  
Howe A(2015)Hormonal modulation of the immune system - A spotlight on the role of progestogens Autoimmun Rev 14 536-42
[6]  
Munier CML(2021)Gender disparity in COVID-19: role of sex steroid hormones Asian Pac J Trop Med 14 5-9
[7]  
Patel SK(2021)Testosterone Deficiency is a risk factor for severe COVID-19 Front Endocrinol 12 694083-52
[8]  
Verthelyi D(2021)Severely low testosterone in males with COVID-19: a case-control study Andrology 9 1043-5
[9]  
Cutolo M(2020)Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) Ann Oncol Off J Eur Soc Med Oncol 31 1040-13
[10]  
Brizzolara R(2006)The relationship between libido and testosterone levels in Aging Men J Clin Endocrinol Metab 91 2509-8